The pre IND product UTRxM1-18 targeting c-MYC
On July 31, 2023
The pre IND product UTRxM1-18 targeting c-MYC in TNBC and across other cancers received thorough feedback and guidance from the FDA. Thanks to all our Team members, mentors, funders and Thermofisher Inc and all our strategic partners who support us as we progress.
